Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4056875 | 0.98 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL366727 | 0.86 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1012343 | 0.85 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1504021 | 0.85 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1283896 | 0.83 | CDK8 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL31265664 | 0.83 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1013888 | 0.83 | PRKCZ (0.53) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL274692 | 0.83 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1264553 | 0.83 | CYP1A2 (0.61) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL2083103 | 0.83 | ALDH1A1 (0.45) | NPC1RAB9ASMN1; SMN2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490458-A | C-3 pyrazole substituted indazole derivative and application thereof | 沈阳药科大学 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025035645-A1 | C-3 PYRAZOLE SUBSTITUTED INDAZOLE DERIVATIVE AND USE THEREOF | 沈阳药科大学 | 2025-02-20 | — | — | WO | disclosed |
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| EP-2890460-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340375-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20150210722-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2890460-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033446-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-03-06 | — | — | WO | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210722-A1 | KINASE INHIBITORS | SYK, SRC, LYN | NPC1 4589/4885RAB9A 1943/4885SMN1; SMN2 4353/4885 |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | NPC1 4774/4885RAB9A 3268/4885SMN1; SMN2 4040/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | NPC1 4635/4885RAB9A 3038/4885SMN1; SMN2 1101/4885 |
| US-20160340375-A1 | KINASE INHIBITORS | SYK, LYN, BTK | NPC1 4578/4885RAB9A 1840/4885SMN1; SMN2 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.